SCHEMBL6861673

SCHEMBL6861673

COc1ccccc1C(=O)N1CCCC1CO

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
HTT P42858 1/20 0.55
TRPV1 Q8NER1 2/20 0.52
HCRTR1 O43613 2/20 0.52
HCRTR2 O43614 2/20 0.52
ROCK2 O75116 1/20 0.52
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
MAPK14 Q16539 1/20 0.51
TP53 P04637 1/20 0.51
PPARG P37231 1/20 0.49
HSP90AA1 P07900 1/20 0.48
HSP90AB1 P08238 1/20 0.48
KDM2B Q8NHM5 2/20 0.48
HSD11B1 P28845 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6866556 1.00 LMNA (0.61) LMNAHTTTRPV1HCRTR1HCRTR2
SCHEMBL6861666 1.00 LMNA (0.61) LMNAHTTTRPV1HCRTR1HCRTR2
SCHEMBL5962884 0.88 LMNA (0.52) LMNATRPV1HCRTR1HCRTR2ROCK2
SCHEMBL8632697 0.86 LMNA (0.57) LMNATRPV1HCRTR1HCRTR2MEN1
SCHEMBL18306276 0.86 KMT2A (0.59) LMNAHTTHCRTR1HCRTR2MEN1
SCHEMBL8632693 0.86 LMNA (0.57) LMNATRPV1HCRTR1HCRTR2MEN1
SCHEMBL5962928 0.85 LMNA (0.49) LMNATRPV1HCRTR1HCRTR2ROCK2
SCHEMBL30514851 0.83 DRD2 (0.57) LMNATRPV1HCRTR1HCRTR2ROCK2
SCHEMBL21177378 0.83 DRD2 (0.57) LMNATRPV1HCRTR1HCRTR2ROCK2
SCHEMBL21177380 0.83 DRD2 (0.57) LMNATRPV1HCRTR1HCRTR2ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
US-6147159-A SUPPORT FOR USE IN SOLID PHASE SYNTHESIS COMPRISING A LINKER GROUP MADE BY HYDROSILATION OF A SOLID SUPPORT HAVING AN ALKENE EXTENDING THEREFROM WITH A DIHYDROGEN SILANE COMPOUND SUCH AS DIHALOSILANE, DIALKOXYSILANE, OR DIALKYLSILANE ARGONAUT TECHNOLOGIES (US) 2000-11-14 US disclosed
WO-1999017869-A2 COMPOSITIONS FOR ORGANIC SYNTHESIS ON SOLID PHASE AND METHODS OF USING THE SAME ARGONAUT TECHNOLOGIES (US) 1999-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R LMNA 3981/4885HTT 76/4885TRPV1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.